Complera, a combination HIV medicine made by Gilead Sciences, was approved by the FDA in 2011. Over the past few years, increasing numbers of patients have alleged that the once-a-day pill has been linked to severe kidney and bone injuries, and that consumers were not adequately warned about these risks.
If you or a loved one has experienced adverse effects including osteoporosis or acute kidney damage after taking Complera, contact HIV Litigation Attorneys™ for a free and confidential consultation. Since Complera’s introduction to the HIV treatment market, there have been a number of disconcerting reports suggesting a connection between Complera use and an increased risk for bone fractures, kidney failure and other life-altering complications.
Our firm is investigating allegations that Complera manufacturer Gilead Sciences was negligent in failing to provide adequate warnings to the public and the medical community about the known risks of antiretroviral medications containing tenofovir disoproxil fumarate (TDF). According to arguments leveled in recent Complera lawsuits, Gilead executives had knowledge — purportedly from internal studies—that pointed to the toxic effects of tenofovir disoproxil fumarate on bones and kidneys. The plaintiffs further contend that the defendant intentionally withheld a safer HIV treatment to maximize their Complera sales until the drug’s exclusivity period was close to an end.
Complera – A Combination HIV Medication
Complera is a once-a-day single-dose regimen for HIV that contains three separate drugs: tenofovir disoproxil fumarate, emtricitabine and rilpivirine. It is prescribed as a first-line treatment for adults diagnosed with HIV infection and children over the age of 12 who meet certain medical requirements.
Complera drug components:
- Tenofovir disoproxil fumarate – nucleoside reverse transcriptase inhibitor
- Emtricitabine –nucleoside reverse transcriptase inhibitor
- Rilpivirine – non-nucleoside reverse transcriptase inhibitor
Of the three active ingredients in Complera, it is the tenofovir disoproxil fumarate that has been associated with bone and liver toxicity and grave health complications. HIV Litigation Attorneys offers zealous representation for individuals who have been harmed after Complera exposure.
Some of the suspected bone and kidney injuries linked to Complera include:
- Bone demineralization
- Bone fractures
- Bone density loss
- Declining kidney function
- Kidney toxicity
- Chronic kidney disease (CKD)
- Renal failure
- Tubular dysfunction
- Fanconi syndrome
Complera Lawsuit Allegations
Pharmaceutical manufacturers have a legal obligation to design, manufacture, and market HIV medications that are safe for their intended purpose and carry adequate warnings about potential risks. Plaintiffs contend that Gilead downplayed the risks of tenofovir disoproxil fumarate in order to promote sales, and that the HIV treatment is dangerous when compared to alternate regimens that could have been placed on the market.
The following are common allegations raised in Complera litigation filed against Gilead Sciences:
- Strict Product Liability – Failure to warn
- Design Defects
- Breach of Express and Implied Warranties
- Marketing Defects
- Fraudulent Concealment
By taking legal action against Gilead Sciences, plaintiffs may be able to seek justice and monetary reparations for their physical, emotional and economic losses. Not every TDF drug side effect will warrant litigation, but serious bone and kidney damage may form the basis of a strong Complera lawsuit. Have you or a loved one suffered renal or bone toxicity from Complera? Find out if you have a viable case against Gilead during a no-obligation case review. Our goal is to provide compassionate yet results-focused representation to clients who need sage legal guidance. Our litigators are on the forefront of HIV drug litigation and leverage years of experience negotiating with Big Pharma and arguing before federal juries.
Compensatory Damages Sought by Plaintiffs
Claimants who file a Complera lawsuit may be able to seek damages for economic and non-economic losses such as:
- Past, present and future medical expenses
- Lost income and wages
- Loss of future earning potential
- Loss of consortium and companionship
- Loss of enjoyment of life
- Pain and suffering
- Emotional distress
- Funeral expenses for a wrongful death
Our pledge is to fight for every dollar to which you are rightfully entitled, with the goal of helping clients achieve justice and some sense of closure. Our team of seasoned litigators collaborates with drug researchers, medical experts and investigators in an effort to uncover the truth behind Gilead’s actions. If the company decided to trade patient safety for billions of dollars in ill-gotten gains, they should be held accountable in a court of law.
Legal Recourse for Bone and Kidney Injuries
HIV Litigation Attorneys™ is poised to help those who have been injured by HIV drugs and will listen to your circumstances to assess the strength of your claims. Complera lawsuits arising from bone and kidney injuries may prevail in the courts, providing substantial money damages for plaintiffs in need.
- LA times, A Question of Timing: A lawsuit claims Gilead Sciences could have developed a less-harmful version of its HIV treatment sooner, https://www.latimes.com/business/la-fi-gilead-20160529-snap-story.html
- Gilead, Complera Patient Information https://www.gilead.com/~/media/files/pdfs/medicines/hiv/complera/complera_patient_pi.pdf
- Aidsinfo.com, Emtricitabine / Rilpivirine / Tenofovir Disoproxil Fumarate https://aidsinfo.nih.gov/drugs/441/complera/0/patient
- POZ, Complera https://aidsinfo.nih.gov/drugs/441/complera/0/patient
- LA West Media, Gilead Sued over HIV Drug Safety https://lawestmedia.com/lawest/gilead-sued-hiv-drug-safety/
- WebMD, FDA Approves Once-Daily HIV Pill Complera https://www.webmd.com/hiv-aids/news/20110811/fda-approves-once-daily-hiv-pill-complera